# Investment Report: PFE
## Executive Summary
Pfizer (PFE) is a pharmaceutical company with a low valuation multiple and a new COVID-19 vaccine candidate in development. Investors should consider the potential benefits of investing in PFE, but also be aware of its reliance on Paxlovid and uncertain pipeline products.

## Investment Decision
HOLD

## Key Reasons Supporting This Decision
PFE's low valuation multiple and recent partnership with BioNTech to develop a new COVID-19 vaccine candidate suggest that it may offer attractive investment opportunities. However, the company's reliance on Paxlovid and lack of clarity surrounding future revenue streams from its pipeline products are concerns.

## Risks To Watch
The main risks associated with investing in PFE include:

*   Uncertainty around future revenue streams from its pipeline products
*   Reliance on a single product (Paxlovid) for significant revenue
*   Potential headwinds from regulatory changes or competition in the pharmaceutical industry